Identification of Whole-Serum Glycobiomarkers for Colorectal Carcinoma Using Reverse-Phase Lectin Microarray

Bertók, Tomáš; Bertóková, Anikó; Jáné, Eduard; Hires, Michal; Aguedo, Juvissan; Potocarova, Maria; Vikartovská, Alica; Kasák, Peter; Borsig, Lubor; Tkáč, Ján

doi:10.3389/fonc.2021.735338

Cited by 14 publications

(10 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…GlcNAc) [27], as published previously [18,19]. The results from the glycoprofiling of fPSA by two lectins (WFL and PHA-E) were obtained as fPSA WFL and fPSA PHA-E values.…”

Section: Analyses and Biostatisticsmentioning

confidence: 86%

“…The copyright holder for this preprint this version posted June 27, 2023. ; https://doi.org/10.1101/2023.06. 27.546717 doi: bioRxiv preprint tumour DNA), proteins, extracellular vesicles (exosomes) and circulating tumour cells [6][7][8][9][10]. Posttranslational modifications of proteins, especially glycosylation, were shown to be strongly associated with disease development and progression [11,12].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Glycoprofiling of proteins as prostate cancer biomarkers: a multinational population study

Pinkeova,

Tomikova,

Bertokova

et al. 2023

Preprint

Self Cite

View full text Add to dashboard Cite

The glycoprofiling of two proteins, the free form of the prostate-specific antigen (fPSA) and zinc-α-2-glycoprotein (ZA2G), was assessed to determine their suitability as prostate cancer (PCa) biomarkers. The glycoprofiling of proteins was performed by analysing changes in the glycan composition on fPSA and ZA2G using lectins (proteins recognising glycans, i.e. complex carbohydrates). The specific glycoprofiling of the proteins was performed using magnetic beads (MBs) modified with horseradish peroxidase (HRP) and antibodies that selectively enriched fPSA or ZA2G from human serum samples. Subsequently, the antibody-captured glycoproteins were incubated on lectin-coated ELISA plates. In addition, a novel glycoprotein standard (GPS) was used to calibrate the assay. The glycoprofiling of fPSA and ZA2G was performed in human serum samples obtained from men undergoing prostate biopsy after an elevated serum PSA, and prostate cancer patients with or without prior therapy. The results are presented in the form of a ROC (Receiver Operating Curve). A DCA (Decision Curve Analysis) to evaluate the clinical performance and net benefit of fPSA glycan-based biomarkers was also performed. While the glycoprofiling of ZA2G showed little promise as a potential PCa biomarker, the glycoprofiling of fPSA would appear to have significant clinical potential. Hence, the GIA (Glycobiopsy ImmunoAssay) test integrates the glycoprofiling of fPSA (i.e. two glycan forms of fPSA). The GIA test could be used for early diagnoses of PCa (AUC=0.84; n=501 samples) with a potential for use in therapy- monitoring (AUC=0.85; n=168 samples). Moreover, the analysis of a subset of serum samples (n=215) revealed that the GIA test (AUC=0.81) outperformed the PHI (Prostate Health Index) test (AUC=0.69) in discriminating between men with prostate cancer and those with benign serum PSA elevation.

show abstract

“…GlcNAc) [27], as published previously [18,19]. The results from the glycoprofiling of fPSA by two lectins (WFL and PHA-E) were obtained as fPSA WFL and fPSA PHA-E values.…”

Section: Analyses and Biostatisticsmentioning

confidence: 86%

Section: Introductionmentioning

confidence: 99%

Glycoprofiling of proteins as prostate cancer biomarkers: a multinational population study

Pinkeova,

Tomikova,

Bertokova

et al. 2023

Preprint

Self Cite

View full text Add to dashboard Cite

show abstract

“…e . GlcNAc) [ 25 ], as published previously [ 18 , 19 ]. The results from the glycoprofiling of fPSA by two lectins (WFL and PHA-E) were obtained as fPSA WFL and fPSA PHA-E values.…”

Section: Methodsmentioning

confidence: 99%

Glycoprofiling of proteins as prostate cancer biomarkers: A multinational population study

Pinkeova,

Tomikova,

Bertokova

et al. 2024

PLoS ONE

Self Cite

View full text Add to dashboard Cite

The glycoprofiling of two proteins, the free form of the prostate-specific antigen (fPSA) and zinc-α-2-glycoprotein (ZA2G), was assessed to determine their suitability as prostate cancer (PCa) biomarkers. The glycoprofiling of proteins was performed by analysing changes in the glycan composition on fPSA and ZA2G using lectins (proteins that recognise glycans, i.e. complex carbohydrates). The specific glycoprofiling of the proteins was performed using magnetic beads (MBs) modified with horseradish peroxidase (HRP) and antibodies that selectively enriched fPSA or ZA2G from human serum samples. Subsequently, the antibody-captured glycoproteins were incubated on lectin-coated ELISA plates. In addition, a novel glycoprotein standard (GPS) was used to normalise the assay. The glycoprofiling of fPSA and ZA2G was performed in human serum samples obtained from men undergoing a prostate biopsy after an elevated serum PSA, and prostate cancer patients with or without prior therapy. The results are presented in the form of an ROC (Receiver Operating Curve). A DCA (Decision Curve Analysis) to evaluate the clinical performance and net benefit of fPSA glycan-based biomarkers was also performed. While the glycoprofiling of ZA2G showed little promise as a potential PCa biomarker, the glycoprofiling of fPSA would appear to have significant clinical potential. Hence, the GIA (Glycobiopsy ImmunoAssay) test integrates the glycoprofiling of fPSA (i.e. two glycan forms of fPSA). The GIA test could be used for early diagnoses of PCa (AUC = 0.83; n = 559 samples) with a potential for use in therapy-monitoring (AUC = 0.90; n = 176 samples). Moreover, the analysis of a subset of serum samples (n = 215) revealed that the GIA test (AUC = 0.81) outperformed the PHI (Prostate Health Index) test (AUC = 0.69) in discriminating between men with prostate cancer and those with benign serum PSA elevation.

show abstract

“…Proteomic technologies applied for liquid biopsies in cancer diagnosis are reviewed in Ding et al [ 83 ]. Moreover, glycomic profiling can be performed by mass spectrometry, but lectin microarrays are increasingly being used [ 84 ].…”

Section: Cancer-associated Alterationsmentioning

confidence: 99%

Molecular Biomarkers in Cancer

2022

View full text Add to dashboard Cite

Molecular cancer biomarkers are any measurable molecular indicator of risk of cancer, occurrence of cancer, or patient outcome. They may include germline or somatic genetic variants, epigenetic signatures, transcriptional changes, and proteomic signatures. These indicators are based on biomolecules, such as nucleic acids and proteins, that can be detected in samples obtained from tissues through tumor biopsy or, more easily and non-invasively, from blood (or serum or plasma), saliva, buccal swabs, stool, urine, etc. Detection technologies have advanced tremendously over the last decades, including techniques such as next-generation sequencing, nanotechnology, or methods to study circulating tumor DNA/RNA or exosomes. Clinical applications of biomarkers are extensive. They can be used as tools for cancer risk assessment, screening and early detection of cancer, accurate diagnosis, patient prognosis, prediction of response to therapy, and cancer surveillance and monitoring response. Therefore, they can help to optimize making decisions in clinical practice. Moreover, precision oncology is needed for newly developed targeted therapies, as they are functional only in patients with specific cancer genetic mutations, and biomarkers are the tools used for the identification of these subsets of patients. Improvement in the field of cancer biomarkers is, however, needed to overcome the scientific challenge of developing new biomarkers with greater sensitivity, specificity, and positive predictive value.

show abstract

Identification of Whole-Serum Glycobiomarkers for Colorectal Carcinoma Using Reverse-Phase Lectin Microarray

Cited by 14 publications

References 59 publications

Glycoprofiling of proteins as prostate cancer biomarkers: a multinational population study

Glycoprofiling of proteins as prostate cancer biomarkers: a multinational population study

Glycoprofiling of proteins as prostate cancer biomarkers: A multinational population study

Molecular Biomarkers in Cancer

Contact Info

Product

Resources

About